Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT02638259. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Parallel-group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of GP2015 and Enbrel® (EU Authorized) in Patients With Moderate to Severe, Active Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic drugs (DMARD) including methotrexate (MTX).
Study identification
- NCT ID
- NCT02638259
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 376 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 20, 2015
- Primary completion
- Dec 28, 2016
- Completion
- Jun 11, 2017
- Last update posted
- Sep 18, 2018
2015 – 2017
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Peoria | Arizona | 85381 | — |
| Novartis Investigative Site | Phoenix | Arizona | 85023 | — |
| Novartis Investigative Site | El Cajon | California | 92020 | — |
| Novartis Investigative Site | Upland | California | 91786 | — |
| Novartis Investigative Site | Van Nuys | California | 91405 | — |
| Novartis Investigative Site | Trumbull | Connecticut | 06611 | — |
| Novartis Investigative Site | Clearwater | Florida | 33765 | — |
| Novartis Investigative Site | Gainesville | Florida | 32607 | — |
| Novartis Investigative Site | Miami | Florida | 33135 | — |
| Novartis Investigative Site | Miami | Florida | 33169 | — |
| Novartis Investigative Site | Orlando | Florida | 32804 | — |
| Novartis Investigative Site | Tampa | Florida | 33603 | — |
| Novartis Investigative Site | Zephyrhills | Florida | 33542 | — |
| Novartis Investigative Site | Lexington | Kentucky | 40615 | — |
| Novartis Investigative Site | Monroe | Louisiana | 71203 | — |
| Novartis Investigative Site | Frederick | Maryland | 21702 | — |
| Novartis Investigative Site | St Louis | Missouri | 63128 | — |
| Novartis Investigative Site | Orchard Park | New York | 14127 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28210 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45219 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73103 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73112 | — |
| Novartis Investigative Site | Rapid City | South Dakota | 57701 | — |
| Novartis Investigative Site | Austin | Texas | 78731 | — |
| Novartis Investigative Site | Carrollton | Texas | 75007 | — |
| Novartis Investigative Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02638259, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2018 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02638259 live on ClinicalTrials.gov.